These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 6374799)

  • 21. Adjuvant chemo- and endocrine therapy alone or in combination in premenopausal patients (GABG Trial 1).
    Kaufmann M; Jonat W; Abel U
    Recent Results Cancer Res; 1989; 115():118-25. PubMed ID: 2696024
    [No Abstract]   [Full Text] [Related]  

  • 22. Adjuvant systemic therapy for resectable breast cancer.
    Bonadonna G; Valagussa P
    J Clin Oncol; 1985 Feb; 3(2):259-75. PubMed ID: 3881562
    [No Abstract]   [Full Text] [Related]  

  • 23. Trials of adjuvant chemotherapy in breast cancer. The experience of the Istituto Nazionale Tumori of Milan.
    Rossi A; Bonadonna G; Tancini G; Bajetta E; Marchini S; Valagussa P; Veronesi U
    Eur J Cancer (1965); 1980; Suppl 1():149-56. PubMed ID: 7032924
    [No Abstract]   [Full Text] [Related]  

  • 24. What is the ideal duration of adjuvant therapy for primary breast cancer: are four cycles of cyclophosphamide and doxorubicin enough?
    Shulman LN
    Curr Oncol Rep; 2001 Nov; 3(6):523-8. PubMed ID: 11595121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal chemotherapy for women with breast cancer: the plot thickens.
    Pater JL; Pritchard KI
    J Clin Oncol; 2003 Mar; 21(6):963-4. PubMed ID: 12637457
    [No Abstract]   [Full Text] [Related]  

  • 26. Doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil for breast cancer.
    Michaelsoln RA
    JAMA; 1995 Sep; 274(10):796-7. PubMed ID: 7650797
    [No Abstract]   [Full Text] [Related]  

  • 27. Clinical trials in advanced breast cancer.
    Schwartsmann G; Pinedo HM
    Eur J Cancer Clin Oncol; 1987 Jun; 23(6):595-7. PubMed ID: 3653182
    [No Abstract]   [Full Text] [Related]  

  • 28. Adjuvant chemo-endocrine therapy or endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV.
    Goldhirsch A; Gelber RD
    Recent Results Cancer Res; 1989; 115():153-62. PubMed ID: 2696027
    [No Abstract]   [Full Text] [Related]  

  • 29. Chemo- or endocrine adjuvant therapy alone or combined in postmenopausal patients (GABG Trial 1).
    Jonat W; Kaufmann M; Abel U
    Recent Results Cancer Res; 1989; 115():163-9. PubMed ID: 2696028
    [No Abstract]   [Full Text] [Related]  

  • 30. Adjuvant systemic therapy in primary breast cancer.
    Mouridsen HT; Palshof T
    Acta Chir Scand Suppl; 1984; 519():43-53. PubMed ID: 6393664
    [No Abstract]   [Full Text] [Related]  

  • 31. [CMF or CAF combination chemotherapy for breast cancer].
    Ota J
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1886-90. PubMed ID: 8978791
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggressive doxorubicin-containing regimen (prednisone, methotrexate, 5-FU, doxorubicin, and cyclophosphamide; PM-FAC) in disseminated estrogen receptor-negative breast cancer.
    Mortimer J; Livingston RB; Hardesty IJ; Groppe CW; Purvis JD; Gupta M; Flournoy N
    Cancer Treat Rep; 1984; 68(7-8):1017-8. PubMed ID: 6744334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current results of the University of Arizona Adjuvant Breast Cancer trials (1974-1984).
    Jones SE; Brooks RJ; Takasugi BJ; Garewal HS; Giordano GF; Ketchel SJ; Jackson R; Heusinkveld RS; Kemmer SR; Moon TE
    Recent Results Cancer Res; 1984; 96():133-40. PubMed ID: 6396766
    [No Abstract]   [Full Text] [Related]  

  • 34. The use of a natural history data base to compare outcome among several trials of adjuvant chemotherapy for stage II breast cancer.
    Jones SE; Moon TE
    Recent Results Cancer Res; 1984; 96():148-54. PubMed ID: 6396768
    [No Abstract]   [Full Text] [Related]  

  • 35. [Importance of dose intensity in chemotherapy--lessons from adjuvant chemotherapy for early breast cancer].
    Tamura K
    Rinsho Ketsueki; 2009 Apr; 50(4):276-81. PubMed ID: 19404020
    [No Abstract]   [Full Text] [Related]  

  • 36. Sequential adjuvant therapy: the Memorial Sloan-Kettering Cancer Center experience.
    Hudis C; Seidman A; Raptis G; Fennelly D; Gilewski T; Baselga J; Theodoulou M; Sklarin N; Moynahan M; Surbone A; Currie V; Lebwohl D; Uhlenhopp M; Crown J; Norton L
    Semin Oncol; 1996 Feb; 23(1 Suppl 1):58-64. PubMed ID: 8629040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant therapy for breast cancer: a brief overview of the NSABP experience and some thoughts on neoadjuvant chemotherapy.
    Fisher B
    Recent Results Cancer Res; 1986; 103():54-68. PubMed ID: 3526476
    [No Abstract]   [Full Text] [Related]  

  • 38. CMF adjuvant programs at the Milan Cancer Institute.
    Bonadonna G; Rossi A; Tancini G; Valagussa P; Veronesi U
    Recent Results Cancer Res; 1984; 96():66-73. PubMed ID: 6549356
    [No Abstract]   [Full Text] [Related]  

  • 39. Combination chemotherapy of solid tumors: an American-Italian collaboration: a celebration of the work of Gianni Bonadonna.
    DeVita VT; Canellos GP
    Tumori; 2016; 102(2):124-6. PubMed ID: 27002947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duration of therapy in adjuvant chemotherapy trials.
    Henderson IC; Gelman RS; Harris JR; Canellos GP
    NCI Monogr; 1986; (1):95-8. PubMed ID: 3534596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.